MTOR and prostate carcinoma: This PTEN mutation leads to the increase of the PI3K/Akt/mTOR pathway and overexpression of Bcl-2, promoting prostate cancer survival and therapeutic resistance (Kim et al., 2017; Pungsrinont, Kallenbach & Baniahmad, 2021).